Navigation Links
Novelos Therapeutics Prices $5.9 Million Public Offering
Date:12/1/2011

MADISON, Wis., Dec. 1, 2011 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCBB: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced the pricing of an underwritten public offering of 9,840,000 units at $0.60 per unit for gross proceeds of $5,904,000.  Each unit consists of one share of common stock and a warrant to purchase one share of common stock.  The warrants will have an exercise price of $0.60 per share and a 5-year term.  The Company has granted the underwriter a 45-day option to purchase up to an additional 15% of the units offered in the public offering to cover over-allotments, if any.  The offering is being made pursuant to an effective registration statement under the Securities Act of 1933, as amended.

Rodman & Renshaw, LLC, a wholly owned subsidiary of Rodman & Renshaw Capital Group, Inc. (NasdaqGM: RODM), is acting as sole underwriter for the offering.  Novelos expects to close the transaction, subject to customary conditions, on or about December 6, 2011.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.  The offering will be made only by means of a prospectus supplement and accompanying prospectus, copies of which may be obtained from Rodman & Renshaw, LLC, Prospectus Department, 1251 Avenue of the Americas, New York, NY, 10020, telephone: 212-356-0500 or email: placements@rodm.com.  Before any investment, an investor should read the prospectus supplement and the accompanying prospectus, including the information incorporated by reference therein, for more complete information about Novelos and this offering.INVESTOR CONTACTSPatrick Genn, Exec. Director

Anne Marie Fields, Senior Vice PresidentNovelos Therapeutics, Inc.

Lippert/Heilshorn & Associates, Inc.Ph: (858) 775-7456

Ph: (212) 838-3777Email: pgenn@novelos.com

Email: afields@lhai.com Novelos Therapeutics, Inc.Madison, WI

Boston, MAThis news release contains forward-looking statements.  You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates.
Such statements are valid only as of today, and we disclaim any obligation to update this information.  These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.  These statements are based on our current beliefs and expectations as to such future outcomes.  Drug discovery and development involve a high degree of risk.  Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our  pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.


'/>"/>
SOURCE Novelos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Novelos Therapeutics Announces Dismissal of Putative Federal Securities Class Action Lawsuit
2. Novelos Therapeutics to Present at the 5th Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference on June 16
3. Nonconformity of NOV002 Used in Phase 3 NSCLC Trial Sponsored by Novelos Therapeutics, Inc to NOV002 (Glutoxim(R)), Used in Phase 1/2 NSCLC and all Previous Trials
4. Unigenes Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist
5. Antiviral Therapeutics - Technologies, Markets and Companies
6. Pain Management Therapeutics Market to 2017 - Price Competition to Intensify Following Patent Expiries of Lyrica and Cymbalta
7. Cara Therapeutics Initiates Phase I Study with Oral Formulation of Novel Peripherally-Acting Kappa Opioid Agonist
8. Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy
9. Prime Therapeutics Launches Retail Medication Therapy Management Program
10. Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference
11. TetraLogic Pharmaceuticals Announces Presentation of Data on Smac Mimetic TL32711 at AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017   ZappRx, Inc ., a digital ... prescribing process, today announced it closed $25 million in Series ... capital firm based in Seattle that ... Partners . The Series B round included participation from ... 2014, and GV (formerly Google Ventures). As part ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
(Date:4/19/2017)... Global Surgical Drainage Device Market: Overview ... remove excess liquid and air. The fluid to be ... lymph. Surgical drains are used in a wide variety ... cardiovascular surgery, neurosurgery, plastic surgery etc. Common use of ... of fluid e.g. blood or pus. Surgical drains are ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... April 21, 2017 , ... Young ... offers services to communities throughout the greater Pittsburgh metropolitan region, is joining forces ... provide adaptive bicycles for differently-abled children. , Variety the Children’s Charity is a ...
(Date:4/21/2017)... , ... April 21, 2017 , ... The Hong Kong ... first 3D printing facility among higher education institutions in Hong Kong to support teaching, ... terms of the range and quantity of facilities in Hong Kong. , With ...
(Date:4/21/2017)... Santa Rosa, CA (PRWEB) , ... April 21, ... ... with St. Joseph Health held the much anticipated Regional Primary Care Spring Symposium ... vital role in the local medical community, offering physicians and healthcare providers an ...
(Date:4/21/2017)... ... 2017 , ... Westside Dental Associates and its owner, Dr. Les ... years, Dr. Latner has become one of the Los Angeles area’s premier dentists. “It’s ... with all their dental needs,” said Dr. Latner, who was recently named Chairperson of ...
(Date:4/21/2017)... CA (PRWEB) , ... April 21, 2017 , ... ... Hospital in Detroit reveals good news for older shoulder replacement patients; post-operative recovery ... function scores from two groups of patients presenting with osteoarthritis following surgery: 262 ...
Breaking Medicine News(10 mins):